PYM-BAC_5和^(131)I-BAC_5联合导向治疗鼻咽癌的实验研究  

Experimental Study of Combined Target Treatments Using PYM-BAC_5 and ^(131)I-BAC_5 to Nasopharyngeal Carcinoma

作　　者：梁治平[1] 刘长征[1] 程竞仪[1] 肖锡宾[2] 张昌卿[2] 梁昌盛[1] 

机构地区：[1]中山大学中山医学院实验核医学教研室,广东广州510080 [2]中山大学肿瘤防治中心中心实验室,广东广州510060

出　　处：《癌症》2003年第8期831-835,共5页Chinese Journal of Cancer

基　　金：国家自然科学基金项目(No.30070231)

摘　　要：背景与目的:现代的肿瘤治疗提倡综合治疗,肿瘤的导向综合治疗具有研究价值。本实验在研究鼻咽癌放射免疫治疗的基础上,观察平阳霉素(pingyangmycin,PYM)和131I与鼻咽癌单抗BAC5的偶联物PYM-BAC5和131I-BAC5对鼻咽癌细胞CNE2的联合抑制效果。方法:用葡聚糖T-40作中间载体偶联PYM和BAC5,用测定抑菌活性和免疫活性的方法鉴定偶联物。用氯胺T法制备131I-BAC5。设置单独用药组(游离PYM,131I-mIgG)、单独导向用药组(PYM-BAC5,131I-BAC5)以及联合导向用药组(PYM-BAC5+131I-BAC5)共5个实验组,用MTT法测定各药物组的抑制作用。结果:PYM-BAC5和游离PYM对CNE2的半数抑制浓度(IC50)分别为46.57μg/ml和316.70μg/ml;131I-BAC5和131I-mIgG对CNE2的IC50分别为4.42×105Bq/ml和>11.10×105Bq/ml;联合用药组中PYM-BAC5的IC50为7.01μg/ml,131I-BAC5的IC50为0.54×105Bq/ml。结论:(1)导向用药组的抑瘤效果明显高于非导向组;(2)联合导向用药组的抑菌效果明显高于单独导向用药组。BACKGROUND &OBJECTIVE:Combined therapy has been advocated for modern tumor treatment; the combined target therapy is a valuable research direction. Based on the previous research of nasopharyngeal carcinoma (NPC) radioimmunotherapy, this experiment was designed to develop two immunoconjugates of the monoclonal antibody BAC5:PYM BAC5 and 131I BAC5, and to assess the inhibition effects of their combined treatment on the NPC CNE 2 cells cultured in vitro. METHODS: Dextran T40 was used as media to link PYM and BAC5. The conjugate PYM BAC5 was identified by testing its immunoactivity and the inhibition to mycobacterium. BAC5 was labeled with 131I by Chloramin T method. Five experimental groups were set up:(1)PYM BAC5 group, (2)free PYM group, (3)131I BAC5 group, (4)131I mIgG group, (5)the combined target treatment group ( 131I BAC5+PYM BAC5). The antitumor effects of the five groups were assessed with MTT method. RESULTS: The 50%inhibition doses(IC50) of PYM BAC5 group and PYM group were 46 57 μg/ml and 316 7 μg/ml, respectively. The IC50 of 131I BAC5 group and 131I mIgG group to CNE2 were 4 42×105 Bq/ml and >11 1×105 Bq/ml,respectively. In the combined target treatment group(PYM BAC5+131I BAC5),the IC50 of PYM BAC5 was 7.01 μg/ml and of 131I BAC5 was 0 54×105 Bq/ml, which much less than other separate treatment groups. CONCLUSION:The inhibition effects of the target treatment (131I BAC5 and PYM BAC5) on the NPC CNE 2 cells are stronger than non target treatment (free PYM and 131I BAC5). The combined target treatment of the two immune (131I BAC5+PYM BAC5) conjugates gets stronger inhibition effects than their separate treatment.

关 键 词：PYM-BAC5 ^131I-BAC5 治疗 鼻咽癌 实验研究 

分 类 号：R739.63[医药卫生—肿瘤]